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Abstract
Rationale: The relationship between clinical phenotype of
childhood primary ciliary dyskinesia (PCD) and ultrastructural
defects and genotype is poorly defined.
Objectives: To delineate clinical features of childhood PCD and
their associations with ultrastructural defects and genotype.
Methods:A total of 118 participants younger than 19 years old with
PCD were evaluated prospectively at six centers in North America
using standardized procedures for diagnostic testing, spirometry,
chest computed tomography, respiratory cultures, and clinical
phenotyping.
Measurements and Main Results: Clinical features included
neonatal respiratory distress (82%), chronic cough (99%), and
chronic nasal congestion (97%). There were no differences in clinical
features or respiratory pathogens in subjects with outer dynein arm
(ODA) defects (ODA alone; n = 54) andODA plus inner dynein arm
(IDA) defects (ODA1 IDA; n = 18) versus subjects with IDA and
central apparatus defects with microtubular disorganization (IDA/
CA/MTD; n = 40). Median FEV1 was worse in the IDA/CA/MTD
group (72% predicted) versus the combined ODA groups (92%
predicted; P = 0.003).Median bodymass indexwas lower in the IDA/
CA/MTD group (46th percentile) versus the ODA groups (70th
percentile; P = 0.003). For all 118 subjects, median number of lobes
with bronchiectasis was three and alveolar consolidation was two.
However, the 5- to 11-year-old IDA/CA/MTD group hadmore lobes
of bronchiectasis (median, 5; P = 0.0008) and consolidation (median,
3; P = 0.0001) compared with the ODA groups (median, 3 and 2,
respectively). Similar findings were observed when limited to
participants with biallelic mutations.
Conclusions: Lung disease was heterogeneous across all
ultrastructural and genotype groups, but worse in those with IDA/
CA/MTD ultrastructural defects, most of whom had biallelic
mutations in CCDC39 or CCDC40.
Keywords: Kartagener syndrome; cilia; respiratory function tests;
X-ray computed tomography scanners; ultrastructure
(Received in original form September 15, 2014; accepted in final form December 8, 2014 )
*These authors were at University of North Carolina School of Medicine at the time of the study.
Supported by National Institutes of Health (NIH) U54HL096458 and 5R01HL071798 funded by the Office of Rare Diseases Research (National Center for
Advancing Translational Science), and administered by NHLBI; CTSA NIH/NCATS UNC ULTR000083; CTSA NIH/NCATS Colorado UL1TR000154; and
Intramural Research Program of NIH/NIAID.
Author Contributions: S. D. Davis, M.R., M.W.L., and M.R.K. designed the study. S. D. Davis, M.W.L., T.W.F., M.R., and M.R.K. prepared the manuscript. H.-S.L.
performed statistical analysis. M.W.L., M.R.K., and J.L.C. reviewed electron photomicrographs. M.W.L., S. D. Davis, S. D. Dell, T.W.F., J.E.P., A.J.S., S.D.S., M.R., and
C.M. recruited and evaluated patients at Genetic Disorders of Mucociliary Clearance Consortium sites. J.P.K. coordinated web-based data entry. M.J.H. developed
standard operating procedure for nasal nitric oxide analyses. M.A.Z. coordinated and validated genetic studies. M.L.C. analyzed chest computed tomography scans.
Correspondence and requests for reprints should be addressed to Stephanie D. Davis, M.D., Indiana University School of Medicine, Riley Hospital for Children,
705 Riley Hospital Drive, ROC 4270, Indianapolis, IN 46202. E-mail: sddavis3@iu.edu
This article has an online supplement, which is accessible from this issue’s table of contents at www.atsjournals.org
Am J Respir Crit Care Med Vol 191, Iss 3, pp 316–324, Feb 1, 2015
Copyright © 2015 by the American Thoracic Society
Originally Published in Press as DOI: 10.1164/rccm.201409-1672OC on December 10, 2014
Internet address: www.atsjournals.org
316 American Journal of Respiratory and Critical Care Medicine Volume 191 Number 3 | February 1 2015
Primary ciliary dyskinesia (PCD) is
a rare lung disease characterized by abnormal
ciliary biogenesis, ultrastructure, and
function. Impaired mucociliary clearance
results in chronic infection and inflammation
of the upper and lower respiratory tract
(1–4). Manifestations include neonatal
respiratory distress, chronic bronchitis
leading to obstructive airways disease and
bronchiectasis, persistent otitis media, and
chronic rhinosinusitis. Other features include
laterality defects, such as situs inversus totalis
or heterotaxy (5). Retrospective studies
suggest that airway disease begins early
(4, 6, 7); however, characterization of clinical
features of PCD in children is incomplete.
Multicenter collaborations have provided
a rigorous approach to diagnosis and disease
characterization, permitting assessment
of age-related trends in clinical features,
pulmonary function, and airway
abnormalities.
Recent advances in PCD genetics
have identified disease-associated mutations
in over 30 genes and strong correlations
between genotype and ultrastructural defect
(1, 2, 8). The most commonly identified
ultrastructural defect, absence of outer
dynein arms (ODA defect), is typically
caused by mutations in genes encoding an
ODA protein, whereas absence of both ODA
and inner dynein arms (ODA1 IDA defect)
is frequently associated with mutations
in genes encoding cytoplasmic proteins
involved in ciliary assembly. Mutations in
genes encoding radial spoke proteins are
linked to central apparatus (CA) defects
(missing central pair, eccentric central pair,
and transposition of outer doublet to the
central pair), which may be apparent in
a small proportion of cilia cross-sections (9).
Two recently described PCD genes, CCDC39
and CCDC40, are associated with a distinct
ultrastructural pattern that had not been
recognized previously: absence of IDA
in conjunction with CA defects and
microtubular disorganization (IDA/CA/
MTD) (9). Other genes (e.g., DNAH11,
which encodes an ODA protein) are
associated with normal axonemal
ultrastructure (10, 11). Present estimates
suggest that 70% of patients with PCD have
a recognizable ultrastructural defect, and
approximately 70% have biallelic mutations
in a recognized disease-associated gene
(1, 8). Considering the pace of gene
discovery, the percentage with a defined
PCD gene defect will continue to rise.
Although genetic defects have been linked
with specific ultrastructural anomalies of
the ciliary axoneme, the relationship between
genotype and clinical phenotype has not been
established. Natural history of pulmonary
involvement has not been systematically
evaluated or linked to mutated genes,
except for a recent report showing milder
lung disease in patients with biallelic mutations
in RSPH1 (12). In this prospective, cross-
sectional study of children with PCD from
North America, we systematically performed
diagnostic tests and defined clinical features,
focusing on structural and physiologic
abnormalities of the lower airways, and
correlated these features with ultrastructural
defect and genotype. We hypothesized that
specific ciliary ultrastructural defects and PCD
disease-causing mutations are associated
with distinct pulmonary phenotypes,
characterized by differing degrees of airflow
obstruction and bronchiectasis.
Methods
Study Sites, Subjects, and
Procedures
Sites in the Genetic Disorders ofMucociliary
Clearance Consortium included University
of North Carolina at Chapel Hill (lead site),
Washington University (St. Louis, MO),
Hospital for Sick Children (Toronto,
Canada), University of Colorado (Aurora,
CO), University of Washington (Seattle,
WA), and Stanford University (Palo Alto,
CA). Study subjects were recruited through
PCD clinics at the participating sites; referral
to these clinics occurred through primary
care physicians, pediatric pulmonologists,
or self-referral. Subjects were younger than
19 years of age with a confirmed diagnosis
of PCD based on ciliary electron microscopy
or identification of biallelic mutations in
a known PCD-associated gene. Institutional
review board approval was obtained at each
site. Informed consent and assent were
acquired from parents and participants,
when appropriate. An observational safety
monitoring board reviewed and approved
the protocols.
Standardized procedures were used for
diagnostic testing and assessment of clinical
features. Subjects underwent nasal epithelial
scrape biopsies for ciliary ultrastructural
analysis. Three masked reviewers at
University of North Carolina at Chapel Hill
evaluated electron micrographs for ciliary
defects defined as absent or truncated ODA,
absent ODA and IDA, absent IDA with
MTD (9), and central pair defects with
absent or off-central pair associated
with transposition of peripheral doublet to
the center. IDA defects were not considered
diagnostic except when apparent on
repeat biopsies (13). Genetic testing was
performed through Sanger sequencing at
the Molecular Genetics Research Core at
the University of North Carolina at Chapel
Hill. Genetic workup included screening for
coding regions and splice junctions for
up to 26 PCD-associated genes, including
mutations in 14 genes identified in our
participants (Table 1; see Table E1 in the
online supplement) (ARMC4, CCDC114,
CCDC39, CCDC40, DNAAF1 [LRRC50],
DNAAF2 [KTU], DNAH5, DNAI1, DNAI2,
HEATR2, LRRC6, RSPH4A, RSPH9, and
SPAG1). Nasal nitric oxide measurements
were performed as previously published
(14). Sputum or deep pharyngeal culture
was processed for bacterial pathogens
at each site’s local clinical laboratory.
Spirometry (in children .3 yr old) and
infant lung function testing under sedation
(in children ,3 yr old) were performed
according to American Thoracic Society/
European Respiratory Society criteria
(15–17). All pulmonary function test data
At a Glance Commentary
Scientific Knowledge on the
Subject: Chronic bronchitis, airflow
limitation, and bronchiectasis have
been demonstrated in retrospective
studies of subjects with primary ciliary
dyskinesia. However, the natural
history of disease and association of
ultrastructural defects and genotype
with respiratory phenotypes are poorly
elucidated in children.
What This Study Adds to the
Field: This multicenter, prospective
study systematically evaluates clinical
features of primary ciliary dyskinesia
in childhood and demonstrates that
those with biallelic mutations in
CCDC39 and CCDC40 or associated
ultrastructural defects (inner dynein
arm/central apparatus/microtubular
defects) have worse lung disease and
poorer growth compared with those
with outer dynein arm defects (defined
by ultrastructure and mutations in
associated genes).
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from children younger than 8 years of
age were overread for quality. Spirometric
measurements were expressed as percent
predicted (18) and infant lung function
as z scores (19, 20).
Chest computerized X-ray
tomographic (CT) images were obtained
according to a protocol limiting radiation
exposure. The controlled breathing
technique under sedation/anesthesia was
used for the youngest subjects as previously
described (21). A radiologist (M.L.C.)
systematically and blindly reviewed chest
CTs for the presence of bronchiectasis and
parenchymal disease in six lobes, including
the lingula as a lobe, using previously
described criteria (22).
Statistical Analyses
Summary statistics are presented for the
entire cohort and for four groups: (1) ODA
defect only, (2) ODA1IDA defect, (3) IDA/
CA/MTD defect, and (4) CA or IDA defect
alone. Group 1 (ODA defect only) was
combined with group 2 (ODA1 IDA
defect) and compared with group 3 (IDA/
CA/MTD defect). Group 4 was not part
of the comparison analyses because of low
sample size (n = 6). Fisher exact test was
used to compare categorical variables, and
Wilcoxon rank-sum test for continuous
variables. A general linear model was
used to examine whether the relationship
between spirometric measurements and age
was different between the combined groups
(1 and 2) and group 3 or the IDA/CA/
MTD group. Two-sided P values less than
0.05 were considered statistically significant.
Analyses were performed using SAS version
9.3 (SAS Institute, Inc., Cary, NC).
Results
Participant Characteristics, Ciliary
Ultrastructural Defects, and PCD
Mutations
One hundred eighteen participants with
PCD were enrolled between 2006 and 2012.
Distribution of ultrastructural defects was
46% ODA alone, 15% ODA1 IDA, 34%
IDA/CA/MTD, and 5% CA or IDA alone
(Table 1). IDA/CA/MTD defects were more
prevalent in subjects younger than 5 years
of age than in older children (55% vs.
27%), whereas ODA alone defects were less
prevalent (17% vs. 55%). Seventy-one
percent (84 of 118) had biallelic gene
mutations (see Table E1).
Demographic and clinical features
of the entire cohort and groups of
ultrastructural defects are described
(Table 2). Most participants had clinical
manifestations of PCD, including (1)
neonatal respiratory distress (82%)
requiring a median of 9.5 days of
supplemental oxygen and a median of 12
days of hospitalization; (2) chronic daily,
“wet” cough (99%) with onset occurring
at a median of 1 month of age; (3)
chronic nasal congestion (97%) with onset
occurring at a median of 1 month of
age; and (4) chronic or recurrent otitis
media (92%). Prevalence of these clinical
manifestations did not differ for the IDA/
CA/MTD group versus the combined ODA
and ODA1 IDA groups. Laterality defects
(situs inversus totalis and heterotaxy) were
observed in 55% of the 118 participants.
Nasal nitric oxide levels were low for
children who were able to cooperate with
palate closure maneuvers (resistor method).
The median value was 13.6 nl/min as
reported previously (14), but did not differ
across groups based on ultrastructural
defects. The only characteristic that differed
significantly was age of evaluation, because
the IDA/CA/MTD group was younger
(P = 0.04) as compared with the combined
ODA and ODA1 IDA groups.
Spirometry, chest CT, and growth
parameters are described in Table 3. Most
children had normal spirometric indices or
mild obstructive impairment, but there was
a wide range with median FEV1 of 89%
predicted and median forced expiratory
flow, midexpiratory phase (FEF25–75) of
68% predicted. Infant lung function tests
in 13 children showed a median FEV0.5
z score of 0.22 that was normal, whereas the
median FEF25–75 z score was diminished
(20.91). Chest CT data revealed prominent
bronchiectasis (median number of lobes
involved, three) and alveolar consolidation
(median number of lobes involved, two).
Growth parameters for most children
were normal, showing median height at
42nd percentile, median weight at 52nd
percentile, and median body mass index
(BMI) at the 63rd percentile.
Lung disease severity and growth
parameters were evaluated by groups
(Table 3). The IDA/CA/MTD group
had worse airflow obstruction, more
radiographic disease, and poorer growth,
compared with the combined ODA and
ODA1 IDA groups. Median FEV1
and FEF25–75 % predicted values were
significantly reduced in the IDA/CA/MTD
group compared with the combined ODA
Table 1. Ciliary Ultrastructural Defects and Mutations in 118 Pediatric Subjects with PCD
Ciliary Defect Type Mutated Gene
<5 yr [N (%)]
(n = 29)




ODA only DNAH5 1 27 28
DNAI1 0 7 7
DNAI2 0 5 5
CCDC114 0 2 2
ARMC4 1 0 1
No gene identified 3 8 11
Total 5 (17%) 49 (55%) 54 (46%)
ODA1 IDA LRRC6 1 2 3
HEATR2 2 0 2
SPAG1 0 1 1
DNAAF2 (KTU) 0 1 1
DNAAF1 (LRRC50) 0 1 1
No gene identified 3 7 10
Total 6 (21%) 12 (13%) 18 (15%)
IDA/CA/MTD CCDC39 7 6 13
CCDC40 8 9 17
No gene identified 1 9 10
Total 16 (55%) 24 (27%) 40 (34%)
CA or IDA alone RSPH4 1 1 2
RSPH9 0 1 1
No gene identified 1 2 3
Total 2 (6%) 4 (4.5%) 6 (5%)
Definition of abbreviations: CA = central apparatus; IDA = inner dynein arm; MTD =microtubular
disorganization; ODA = outer dynein arm; PCD = primary ciliary dyskinesia.
71% of patients had identified biallelic gene mutations.
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and ODA1 IDA groups (P = 0.003
and P = 0.002 for FEV1 and FEF25–75,
respectively). The IDA/CA/MTD group
had lower FEV1 and FEF25–75 values
(72 and 49% predicted, respectively)
compared with the combined ODA and
ODA1 IDA groups (FEV1, 92%; FEF25–75,
73% predicted). Among the children who
performed infant lung function tests,
median FEF25–75 z score was diminished in
the IDA/CA/MTD group (z score, 21.02)
compared with the combined ODA and
ODA1IDA groups (z scores, 0.77 and
20.84, respectively; P = 0.023) (Table 3).
The median number of lobes with
alveolar consolidation was greater in the
IDA/CA/MTD group (median, three)
compared with the combined ODA and
ODA1 IDA groups (median, two) (P =
0.001). The IDA/CA/MTD group weighed
less (P, 0.0001), were shorter (P = 0.036),
and had a decreased BMI (P = 0.003)
compared with the combined ODA and
ODA1 IDA groups. The IDA/CA/MTD
group had a median weight at the 39th
percentile, median height at the 36th
percentile, and median BMI value at
the 46th percentile compared with the
combined ODA and ODA1 IDA
groups (68th, 48th, and 70th percentile,
respectively). When analyses were limited
to children who had defined biallelic
genetic mutations (n = 84), findings were
similar except for height (P = 0.129).
In Figures 1A and 1B, FEV1 and
FEF25–75 % predicted, respectively, are
plotted against age in this cross-sectional
study. Although FEV1 and FEF25–75 %
predicted remained constant with
increasing age among participants with
ODA (group 1) and ODA1 IDA (group 2)
defects, both measures declined with
advancing age in participants with IDA/
CA/MTD (group 3) defects; slopes for the
combined ODA groups (ODA [group 1]
and ODA1 IDA [group 2]) versus the
IDA/CA/MTD group are significantly
different (P = 0.003 and P = 0.010 for FEV1
and FEF25–75, respectively). The slope of
FEV1 change in the IDA/CA/MTD group
was 23.88% predicted per year, whereas
the slope of the combined ODA and
ODA1 IDA groups was nearly flat,
0.085% predicted per year. For FEF25–75
measures, the slopes were 24.09%
predicted per year and 0.30% predicted per
year for the IDA/CA/MTD and combined
ODA and ODA1 IDA groups,
respectively.
In Figures 2A and 2B, the number
of lobes with bronchiectasis and alveolar
consolidation, respectively, are plotted
according to age groups. For all ages, the
extent of bronchiectasis and alveolar
consolidation varied, ranging from zero to
six affected lobes. For subjects younger than
5 years, the number of lobes with alveolar
consolidation or bronchiectasis in the
combined ODA and ODA1 IDA groups
versus the IDA/CA/MTD group was not
different (P = 0.860 and 0.466, respectively).
Among children 5–11 years of age, the
IDA/CA/MTD group had more lobes with
bronchiectasis (P = 0.0008) and alveolar
consolidation (P = 0.0001) than the
combined ODA and ODA1 IDA groups.
For the 12–18 years age group, the IDA/
CA/MTD group did not seem to have
more lobes involved, although there were
relatively few subjects with IDA/CA/MTD
defects in this age group (n = 6).
Table 4 describes the respiratory
microbiology. For all 118 subjects,
predominant pathogens were Staphylococcus
aureus (19%), Haemophilus influenza
(22%), Streptococcus pneumonia (14%),
and Moraxella catarrhalis (8%).
Nonmucoid and mucoid Pseudomonas
aeruginosa were recovered in 6 and
3% of subjects, respectively. Samples
were expectorated sputum in 66% and
pharyngeal swabs in 34%. There were
no significant differences in respiratory
bacterial isolates between children with
IDA/CA/MTD defects compared with
those with ODA and ODA1 IDA defects.
Table 2. Demographics and Clinical Characteristics








Only (n = 6) P Value*
Male sex, % 53 50 61 53 50 1.00
White race, % 81 87 61 80 100 1.00
Age, yr 8 (5–11) 8 (6–12) 5 (3–11) 7 (2.5–10) 12 (4–14) 0.04
Nasal nitric oxide (nl/min, palate












Laterality defect, % 55 59 67 50 17 0.32
Neonatal respiratory distress, % 82 78 89 88 67 0.44
Supplemental oxygen at birth, d 9.5 (3–18.5) 9 (4–15) 12.5 (4–20) 11 (7–25) 0 (0–4.5) 0.23
Newborn hospitalization, d 12 (7–20) 10.5 (7–18) 14 (7–20.5) 13 (8–24) 10 (6–10) 0.25
Chronic cough, % 99 100 100 98 100 0.36
Age of onset of wet cough, mo 1 (1–3) 1 (1–6) 1 (1–1) 1 (1–5.5) 1 (1–1) 0.7
Pneumonias, % 81 80 72 83 100 0.63
Number of acute pneumonias over
5 yr (or lifetime if ,5 yr old)
3 (1–6) 3 (1–6) 2 (1–5) 1.5 (1–6) 5 (3–10) 0.5
Number requiring hospitalizations 1 (0–2) 1 (0–2) 1 (1–2) 1 (0–2) 1 (0–2) 0.59
Chronic nasal congestion, % 97 100 89 98 100 1.00
Age of onset of chronic nasal
congestion, mo
1 (1–1) 1 (1–1) 1 (1–1) 1 (1–1) 1 (1–1) 0.64
Chronic/recurrent otitis media, % 92 93 89 90 100 0.74
Age of onset of otitis media, mo 4 (2–8) 3 (2–7) 6 (2–13.5) 3.5 (3–6) 4.5 (2–6) 0.94
Definition of abbreviations: CA = central apparatus; IDA = inner dynein arm; MTD =microtubular disorganization; ODA = outer dynein arm.
% or median (first quartile–third quartile).
*P values for the comparison between the group of IDA/CA/MTD defect and the combined groups of ODA defect only and ODA1IDA defect.
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Historical review of prior respiratory
culture results revealed transient infection
with several organisms in most participants:
S. aureus, H. influenzae, S. pneumonia, and
M. catarrhalis were recovered in 35, 50, 30,
and 19% of the children, whereas
nonmucoid and mucoid P. aeruginosa were
recovered in 20 and 5% of the children,
respectively. There was no identifiable
Table 3. Markers of Disease Severity by PCD Group









(n = 6) P Value*
Height, percentile† 42 (19 to 70) n = 106 42 (20 to 83) n = 51 63 (15 to 77) n = 16 36 (13 to 60) n = 34 44 (24 to 62) n = 5 0.036
Weight, percentile 52 (17 to 80) n = 118 67 (30 to 91) n = 54 76 (34 to 82) n = 18 39 (13 to 52) n = 40 62 (47 to 81) n = 6 ,0.0001
BMI, percentile† 63 (32 to 82) n = 106 68 (32 to 92) n = 51 74 (41 to 82) n = 16 46 (26 to 65) n = 34 80 (71 to 84) n = 5 0.003
FEV1, % pred 89 (67 to 99) n = 86 93 (78 to 101) n = 46 91 (74 to 99) n = 12 72 (58 to 88) n = 24 86 (77 to 93) n = 4 0.003
FEF25–75, % pred 68 (48 to 80) n = 86 73 (57 to 80) n = 46 78 (59 to 94) n = 12 49 (32 to 64) n = 24 75 (53 to 88) n = 4 0.002
Infant FEV0.5,
z score
0.22 (0.12 to 0.31) n = 13 1.00 (0.57 to 1.43) n = 2 0.20 (0.02 to 0.31) n = 3 0.14 (0.01 to 0.22) n = 7 0.38 n = 1 0.144
Infant FEF25–75,
z score









2 (1 to 3) n = 118 1.5 (1 to 3) n = 54 2 (1 to 3) n = 18 3 (2 to 4) n = 40 2 (1 to 2) n = 6 0.001
Definition of abbreviations: BMI = body mass index; CA = central apparatus; CT = computed tomography; FEF25–75 = forced expiratory flow, midexpiratory
phase; IDA = inner dynein arm; MTD = microtubular disorganization; ODA = outer dynein arm; PCD = primary ciliary dyskinesia.
Median (first quartile to third quartile).
*P values for the comparison between the group of IDA/CA/MTD defect and the combined groups of ODA defect only and ODA1IDA defect.






























































Figure 1. Pulmonary function measures (A) FEV1 and (B) forced expiratory flow, midexpiratory phase (FEF25–75) % predicted plotted as a function of age in
pediatric subjects with primary ciliary dyskinesia (n = 82). Circles represent subjects with primary ciliary dyskinesia who have outer dynein arm (ODA)
defects that include absent or truncated ODA and combined absence of ODA and inner dynein arm (IDA) (groups 1 and 2). Squares represent individuals
who have microtubular disorganization (MTD) associated with IDA and central apparatus (CA) defects (IDA/CA/MTD, group 3). Filled symbols identify
subjects who have known biallelic genetic defects, whereas open symbols indicate those subjects for whom the genetic basis of their disease is yet unknown. In this
cross-sectional study, the association of both FEV1 and FEF25–75 with age declines for subjects with IDA/CA/MTD derangements (group 3) compared with the
combined ODA groups, ODA (group 1) and ODA1 IDA (group 2) (P=0.003 and 0.010, respectively). The slope of FEV1 change in the IDA/CA/MTD group was
23.88% predicted per year (dashed line), or23.90% predicted per year for subjects with known genetic defects. The FEV1 slope of the combined ODA and ODA1
IDA groups was 0.085% predicted per year (solid line), or 0.64% predicted per year in known genetic defects. The slope of FEF25–75 change was24.09% predicted
per year (dashed line), or 25.03% predicted per year in known genetic defects, in the IDA/CA/MTD cohort, and 0.30% predicted per year (solid line), or 0.70%
predicted per year in known genetic defects, for the combined ODA and ODA1 IDA groups.
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association between pathogen and indices
of lung disease severity.
Discussion
We describe clinical features and spectrum
of lung disease in a multicenter cohort
of children with confirmed PCD and/or
biallelic PCD-associated mutations.
Prominent clinical features included
neonatal respiratory distress, early onset
persistent chronic cough and nasal
congestion, and recurrent otitis media. Situs
inversus totalis or situs ambiguous was
identified in slightly more than half (55%) of
the subjects, likely reflecting ascertainment
bias associated with recognition of laterality
defects. Ultrastructural and genotype
analysis did not reveal significant differences
in prevalence of clinical features across
groups. However, structural and physiologic
markers of lung disease severity were
heterogeneous across groups, and worse in
those with an IDA/CA/MTD ultrastructural
defect, most of whom had biallelic CCDC39
and CCDC40 mutations.
Previous studies evaluating clinical
features of PCD during childhood have been
limited by retrospective data collection,
small sample sizes, addition of adult data,
and less rigorous diagnostic confirmation,
although most were conducted before
newer diagnostic tests became available
(4, 7, 23–25). Individuals with recently
recognized ultrastructural defects, such
as IDA/CA/MTD, may not have been
included in earlier studies or may have been
classified as IDA defect. In some prior
studies, up to a third of subjects included
in the “PCD” group had an isolated IDA
defect, which can be a nonspecific, transient
finding unrelated to genetic defects. A
recent study (13) revealed that a substantial
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Figure 2. Radiographic findings of (A) bronchiectasis and (B) alveolar consolidation in individual lobes and lingula in pediatric subjects with primary ciliary
dyskinesia (n = 112), segregated into different age groups (,5 yr, 5–11 yr, and 12–18 yr of age). Circles represent subjects with primary ciliary dyskinesia
who have outer dynein arm (ODA) defects, which include absent or truncated ODA and complete absence of both ODA and inner dynein arm (IDA)
(groups 1 and 2). Squares represent individuals who have microtubular disorganization (MTD) associated with IDA and central apparatus (CA) defects (IDA/
CA/MTD, group 3). The vertical lines represent median and first and third quartile. Subjects with IDA/CA/MTD defects between the ages of 5 and 11
years have increased bronchiectasis (P = 0.0008) and alveolar consolidation (P = 0.0001) compared with the combined ODA groups, ODA (group 1)
and ODA1 IDA defects (group 2).









CA or IDA Alone
(n = 6) P Value*
Oropharyngeal flora only, % 34 35 33 33 33 0.84
Staphylococcus aureus, % 19 22 17 15 17 0.61
Haemophilus influenza, % 22 22 28 23 0 1.00
Streptococcus pneumoniae, % 14 13 22 13 0 0.78
Moraxella catarrhalis, % 8 6 6 10 17 0.45
Nonmucoid Pseudomonas aeruginosa, % 6 4 0 13 0 0.10
Mucoid P. aeruginosa, % 3 2 0 5 17 0.29
Nontuberculous mycobacteria, % 3 4 0 5 0 0.62
Other, % 15 13 28 13 17 0.78
Definition of abbreviations: CA = central apparatus; IDA = inner dynein arm; MTD = microtubular disorganization; ODA = outer dynein arm; PCD = primary
ciliary dyskinesia.
*P values for the comparison between the group of IDA/CA/MTD defect and the combined groups of ODA defect only and ODA1IDA defect.
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defects had normal axonemal ultrastructure
on repeat testing. Clinical features in the
current study are described in more detail
than in our earlier studies (4). Specifically,
we define age of onset of “wet” cough, nasal
congestion, and otitis media, and document
that these hallmark features typically
begin during the first 3 months of life. We
collected more details regarding neonatal
manifestations, including number of days
requiring supplemental oxygen support
(median, 9.5 d) and days hospitalized
(median, 12 d). Given our detailed clinical
phenotyping, we can now define key
clinical features early in PCD.
In the past, PCD has been considered
a “milder” lung disease than cystic fibrosis
(CF). A previous cross-sectional study
in pediatric and adult subjects with
PCD showed that FEV1 decline (20.8%
predicted per year) was slower than
that reported for CF at the time
(23.6% predicted per year) (4). The first
longitudinal study in PCD (24 adults and
12 children) demonstrated a wide range
of lung function, but values remained
stable over time after initiation of airway
clearance techniques and culture-directed
antibiotic therapy (24). In another
multicenter study of 158 children with
PCD, pulmonary function and growth
parameters varied widely at time of
presentation, but remained stable over
a period of 2–6 years (26).
In contrast, a longitudinal study of
74 subjects with PCD (median age at
diagnosis, 8 yr) found significant decline
in lung function over three decades (7). This
variability in lung function and observed
rate of decline emphasizes the need to
better characterize factors contributing
to pulmonary deterioration in the
PCD population. Unlike a recent study
suggesting that lung disease is not
influenced by ultrastructural phenotype
(27), our study found that children with
a specific PCD ultrastructural defect, IDA/
CA/MTD, many of which are associated
with biallelic mutations in CCDC39 and
CCDC40, have worse pulmonary function
than that seen in similar aged children with
ODA defects and similar to that found in
patients with CF. These novel findings open
new lines of research to better understand
mechanisms involved and implications
of these observations for clinical care.
This study is the first to systematically
assess structural changes on chest CT by
ultrastructural defect or genotype in a young
PCD population and demonstrates that
alveolar consolidation and bronchiectasis
were common findings among all
ultrastructural groups. The IDA/CA/MTD
group had significantly more lobes of
consolidation compared with the combined
ODA and ODA1 IDA groups. Relatively
few studies have evaluated structural
disease in a large PCD population and most
included only older children (23, 25, 28,
29). Case reports have shown that
bronchiectasis can occur in infants with
PCD (6).
Growth parameters of most children
in our study were normal, but subjects with
the IDA/CA/MTD defect and/or biallelic
mutations in CCDC39 or CCDC40 had
impaired growth parameters, when
compared with the combined ODA
and ODA1 IDA groups. Studies in
other lung diseases including chronic
obstructive pulmonary disease (30, 31),
bronchopulmonary dysplasia (32), and CF
(33–35) have shown that subjects with
impaired growth and/or low BMI tend to
have poorer lung function and pulmonary
outcomes. The poor growth parameters in
the IDA/CA/MTD group may reflect or
contribute to severity of lung disease.
Parallel to our results, other investigators
(26) reported normal growth parameters
in children with PCD, with relatively few
subjects who had a low BMI; however, these
investigators did not evaluate growth
parameters based on ultrastructural ciliary
defects or gene mutation. Unlike a recent
publication (36) that reported that BMI
was reduced in subjects with DNAH5 and
DNAI1 (both ODA genes), our subjects with
ODA defects (which include individuals
with biallelic DNAH5 and DNAI1
mutations) had normal growth parameters.
The higher prevalence of IDA/CA/
MTD defects in our preschool age group
(55%) compared with those 5–18 years
of age (27%) is worth highlighting. Perhaps
patients with this defect are diagnosed
earlier because they have more severe
symptoms in infancy and early childhood,
although we were unable to identify
differences in onset of respiratory
symptoms or management among subjects
with different ultrastructural defects.
Interestingly, infant lung function testing
showed that expiratory flow rates were
diminished in the group with IDA/CA/
MTD defects compared with those with
ODA and ODA1 IDA defects. Although
infant lung function testing was performed
in only a small subset of patients based on
age at enrollment, these findings provide
preliminary evidence of the presence of
early airflow limitation and airway disease
in infancy.
Association of PCD with biallelic
CCDC39 and CCDC40 mutations has
only recently been recognized, and
understanding of pathophysiology is
rapidly evolving. Mutations in CCDC39 and
CCDC40 are relatively common in PCD
(9) and both mutant genes lead to similar
defects in axonemal architecture with
inconsistent ultrastructual abnormalities,
characterized by absent IDA with
displacement or absence of the central pair
and mislocalized peripheral doublets in
some but not all cilia. Associated motility
defects range from stiff cilia with reduced
mean ciliary beat frequency and amplitude
to complete immotility (9, 37, 38). CCDC39
and CCDC40 are evolutionarily conserved
genes and encode structurally related
coiled-coil domain-containing proteins
localized to the axoneme. The coiled-coil is
a common structural domain in eukaryotic
and prokaryotic proteins and can act
as an adapter between molecules (39).
CCDC39 and CCDC40 interact with
components of the nexin-dynein regulatory
complexes and are involved in IDA
attachment (40). CCDC39 seems to confer
stability of the nexin-dynein regulatory
complexes or is involved in protein
transport, because it contains structural
maintenance of chromosome-like domains
analogous to those found in other ciliary
and centrosomal proteins involved in
intracellular transport (37). CCDC40
mutant cells lack CCDC39 in the axoneme,
indicating that it is required for transport
of CCDC39 into the axoneme (38).
CCDC39 and CCDC40 may have roles
in nexin-dynein regulatory complexes
assembly, microtubule attachment, or serve
as a docking domain. Other mutated genes,
particularly the ODA1 IDA genes, can
lead to marked ciliary dysmotility or
immotility, thus abnormal ciliary motion
cannot fully explain the severe pulmonary
phenotype in PCD subjects with CCDC39
and CCDC40 mutations.
In summary, we report clinical features
of childhood PCD based on ultrastructural
axonemal defects and genotype. In this
cross-sectional study, there was significant
heterogeneity of lung disease beginning
at an early age, but subjects who had
an IDA/CA/MTD defect, usually linked
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to mutations in PCD-associated genes
(CCDC39 and CCDC40), presented earlier and
had worse lung disease by both functional and
structural assessment (spirometry and CT
scans) and poorer nutritional status. Given
these findings, longitudinal analyses are
needed to confirm this pattern in individual
patients and better characterize pulmonary
function decline with age. We expect that
other genotype-phenotype relationships
will be identified in PCD, which will more
fully define the influence of specific
genetic defects on lung disease. PCD has
classically been difficult to diagnose
because of technical challenges associated
with electron microscopy and video
microscopy; patients often have to be
evaluated at specialty centers to confirm
the diagnosis (41). Genetic testing offers
the benefit of not only confirming
diagnosis, but also, as demonstrated in
this study may contribute to prognosis.
These findings provide greater insights
into development and progression of lung
disease beginning in infancy, and could
potentially allow for more personalized
monitoring and treatment of these
children. n
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